Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double blind controlled trial examining the impact of
incorporating a single intraoperative intravenous magnesium bolus and infusion into a
preexisting Enhanced Recovery After Surgery (ERAS) protocol for colorectal surgery in place
of preoperative oral pregabalin. These protocols are pathways designed with the goal of
achieving early surgical recovery by utilizing a constellation of perioperative care
techniques that include the use of opioid-sparing pain medications, minimally invasive
approaches, and prevention of post-operative nausea and vomiting, among others. Intravenous
magnesium has shown to be an effective non-opioid analgesic in abdominal surgeries that
decreases total opioid consumption, pain, and improves recovery. The purpose of this study is
to evaluate whether or not the addition of intravenous magnesium to our institutional ERAS
protocol will improve specific outcome measures, and provide additional benefits when
compared to oral preoperative pregabalin. The primary outcome is the patient's quality of
recovery based on the "Quality of Recovery - 40 Questionnaire" (QOR 40), and secondary
outcomes will be opioid consumption, pain, shivering, sedation scores, acute kidney injury,
gastrointestinal function, respiratory function, and hospital length of stay.